Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO

Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO

SHANGHAI, April 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase Ib/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 combined...

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II...

Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SHANGHAI, March 26, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of 6 studies as poster presentation at the AACR Annual Meeting to be held...

Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND

SHANGHAI, July 22, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National...

menu
menu